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Abstract
Background: It is well established that adipose tissue plays a key role in energy storage and
release but is also a secretory organ and a source of stem cells. Among different lineages, stem cells
are able to differentiate into adipocytes and osteoblasts. As secreted proteins could regulate the
balance between both lineages, we aimed at characterizing the secretome of human multipotent
adipose-derived stem cell (hMADS) at an early step of commitment to adipocytes and osteoblasts.
Results:  A proteomic approach, using mono-dimensional electrophoresis and tandem mass
spectrometry, allowed us to identify a total of 73 proteins at day 0 and day 3 of adipocyte and
osteoblast differentiation. Analysis of identified proteins showed that 52 % corresponded to
classical secreted proteins characterized by a signal peptide, that 37 % previously described in the
extracellular compartment were devoid of signal peptide and that 11 % neither exhibited a signal
peptide nor had been previously described extracellularly. These proteins were classified into 8
clusters according to their function. Quantitative analysis has been performed for 8 candidates:
PAI-1, PEDF, BIGH3, PTX3, SPARC, ENO1, GRP78 and MMP2. Among them, PAI-1 was detected
at day 0 and day 3 of osteoblast differentiation but never in adipocyte secretome. Furthermore we
showed that PAI-1 mRNA was down-regulated in the bone of ovariectomized mice.
Conclusion: Given its regulation during the early events of hMADS cell differentiation and its
status in ovariectomized mice, PAI-1 could play a role in the adipocyte/osteoblast balance and thus
in bone diseases such as osteoporosis.
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Background
Adipose tissue is no longer considered as a mere energy
reservoir but it plays also an endocrine role, releasing a
panoply of secreted molecules, i.e. adipokines such as lep-
tin, adiponectin, plasminogen activator inhibitor 1 (PAI-
1), vaspin and tumor necrosis factor α (TNFα) [1,2]. Fur-
thermore, adipose tissue is a source of stem cells, repre-
senting a promising tool for pharmacological studies and
clinical applications [3]. A balanced development of adi-
pose tissue is of crucial importance to ensure some of the
most important physiological functions, including repro-
duction, haemostasis, angiogenesis, blood pressure and
immune function [1,4]. Alterations of fat cell number and
size are present in lipodystrophy and obesity that are asso-
ciated to type 2 diabetes [5]. Another condition altering
fat cell formation is osteoporosis, where an imbalance
between adipocytes and osteoblasts in bone marrow is
observed. Aging, menopause, glucocorticoid treatment or
alcohol abuse can lead to an increase in bone marrow adi-
posity [6,7]. To date, several issues are still pending, for
instance whether infiltration of fat in bone marrow causes
low bone mass or is due to bone loss [6,7]. Since adi-
pocytes and osteoblasts share the same mesenchymal pre-
cursor, the study of the adipocyte/osteoblast balance
represents a worthy challenge to treat adipose tissue and
bone disorders. It is well described that secreted leptin and
adiponectin can affect bone formation both directly on
osteoblastogenesis and indirectly by acting on osteoclas-
togenesis [6,8-10]. Several molecules secreted by osteob-
lasts such as Wnt and bone morphogenetic protein favor
osteogenesis at the expense of adipogenesis [7,11], thus
pointing out a crosstalk between both lineages.
During the last two decades, a large number of molecular
regulators of adipogenesis and osteogenesis have been
described. Among them, peroxisome proliferator-acti-
vated receptor γ (PPARγ) and CCAAT/enhancer-binding
proteins (C/EBPs) are well recognized factors that play
major roles in adipogenesis [12], whereas runt-related
transcription factor 2 (runx2), distal-less homeobox 5
(dlx5), muscle segment homeobox 2 (msx2) and osterix
represent master regulators of osteogenesis [6,13].
In the present work, we aimed at identifying molecules
secreted at early step of differentiation of human mesen-
chymal stem cells towards adipocytes and osteoblasts. To
address this point, we used a cellular model recently
established in our laboratory, termed hMADS cells
(human multipotent adipose tissue-derived stem cells).
hMADS cells, isolated from the adipose tissue of young
donors, present extensive capacities of self-renewal, clo-
nogenicity and multipotency, as they fully differentiate
into adipocytes, osteoblasts, myoblasts and chondrocytes
while exhibiting a normal karyotype [14-17].
Recently, proteomic approaches have been applied to
study rodent and human adipose tissue secretome using
cellular models that focused mainly on late events of adi-
pogenesis [18-22]. Moreover, with respect to early events
of osteogenesis, a characterization of secreted molecules
from osteoblasts has not been so far reported.
Herein we have identified 73 proteins by a proteomic
approach and confirmed these findings by Western-blot
for 8 candidates. These proteins and their involved path-
ways, in particular the plasminogen system, could play an
important role in regulating the adipocyte/osteoblast bal-
ance.
Results
Characterization of the secretome of hMADS cells 
committed towards adipocytes and osteoblasts
hMADS cells differentiate into adipocytes and osteoblasts,
as shown in Figure 1A. Gene expression of representative
markers of adipocyte (adiponectin) and osteoblast differ-
entiation (alkaline phosphatase) are reported and in
agreement with previously published data [14-17]. The
terminal differentiation of hMADS cells into adipocytes
and osteoblasts is also illustrated by the typical cellular
morphology as shown in Figure 1B.
In order to analyze the secretome at early step of adipo-
genesis and osteogenesis of hMADS cells, secretion media
at day 3 of differentiation into adipocytes and osteoblasts
were compared with those of cells at day 0. Cells were
washed 3 times with PBS and incubated for 6 h with
serum-free culture medium, containing 0.1 μg/ml of
transferrin without differentiation inducers. At the end of
this incubation period, media were harvested, filtered and
concentrated. Very low cell death or cell lysis occurred
during the incubation period, as checked by microscopic
analysis and lactate dehydrogenase activity measurements
[see Additional file 1]. Four μg of each protein sample
were loaded onto one-dimensional SDS-PAGE and
stained with Bio-Safe Coomassie Stain. A representative
gel is reported in Figure 1C. The excised bands from the
SDS-PAGE were cut, trypsin digested and analyzed by
mass spectrometry. The list of the identified proteins is
reported in Table 1. Further details about the peptides
identified for each protein are available in Table 1S [see
Additional file 2].
Seventy three proteins were classified according to their
function and localization, determined by the Meta search
engine Bioinformatic Harvester. As reported in Figure 2A
and Table 1, a large amount of identified proteins (52 %)
corresponded to "classical" secreted proteins character-
ized by a signal peptide. Among them, we found several
components of the extracellular matrix (fibronectin, colla-
gens etc...), proteases, serine protease inhibitors (serpinsBMC Molecular Biology 2008, 9:26 http://www.biomedcentral.com/1471-2199/9/26
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such as PAI-1, pigment epithelium derived factor (PEDF)
and Plasma protease C1 inhibitor) and other proteins
involved in collagen catabolism, protein folding/turnover
and growth regulation. In differentiating osteoblasts at
day 3, periostin, described previously to be associated
with osteoblast differentiation [23] was identified,
whereas its presence was not detected in secretion media
of differentiating adipocytes. A high percentage of pro-
teins (37 %), devoid of signal peptide, was also detected
into the secretion medium. These proteins were labelled
as extracellular since they have been previously described
in the extracellular compartment. Some of these proteins
were metabolic enzymes such as α-enolase (ENO1) and
pyruvate kinase, cytoskeletal components or heat shock/
chaperone proteins. Similar findings from literature have
been reported (see references in Table 1) strengthening
actually their presence in the extracellular medium of var-
ious cellular models as well as in the murine/human
bloodstream. The remaining proteins (11 %) did not
exhibit a signal peptide (in: intracellular) and, to the best
of our knowledge, have not been so far described extracel-
lularly and did not represent artefacts as cell lysis was very
low [see Additional file 1]. These proteins are only puta-
tively secreted and indicated by an asterisk in Table 1. As
illustrated by the Venn diagram in Figure 2B, the secretion
of 21 proteins resulted to be similar under the three cul-
ture conditions, while 28 proteins were specifically
secreted under adipogenic condition compared to 3 pro-
teins under osteogenic condition.
Finally, hMADS cell secretome was clustered in 8 main
groups, as indicated in Table 1 and Figure 3. These clusters
include: proteases, protease inhibitors, extracellular
matrix (ECM) components, anti-inflammatory/anti-oxi-
dant proteins, metabolic enzymes, cytoskeletal compo-
nents, heat shock/protein folding proteins and other
proteins. These clusters illustrated the diversity of hMADS
cell secretome, thus suggesting that some of these proteins
could be involved in the regulation of the adipocyte/oste-
oblast balance.
Validation of protein expression of selected candidates
Mass spectrometry identification data were validated for 8
candidates, selecting them from different clusters, i.e. 1
protease, 2 protease inhibitors, 2 ECM components, 1
anti-inflammatory/anti-oxidant protein, 1 metabolic
enzyme and 1 heat shock protein. Western blots or zymo-
grams were employed to supplement the identification by
mass spectrometry and to determine the expression pro-
file among three different sets of conditions (day 0 and
Analysis of terminal differentiation of hMADS cells into adipocytes and osteoblasts and Coomassie Blue staining of hMADS cell  secretome Figure 1
Analysis of terminal differentiation of hMADS cells into adipocytes and osteoblasts and Coomassie Blue stain-
ing of hMADS cell secretome. A. qRT-PCR analysis of mRNA levels of specific adipogenic (adiponectin) and osteogenic 
(alkaline phosphatase) markers at day 3 and day 14 of differentiation as compared to day 0. The data are representative of 
three independent experiments. B. Microphotographs of hMADS cells differentiated into adipocytes and osteoblasts at day 14. 
Bar scale = 50 μm. C. Representative gel of secreted proteins from hMADS cells at day 0 and day 3 of differentiating adi-
pocytes (adipo) and osteoblasts (osteo) after 6 h of incubation. The gel is representative of 3 independent experiments.
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Table 1: Identification of proteins in the secretome of hMADS cells at early step of adipogenesis and osteogenesis.
ID Protein name Function Mw kDa Loc Day 0 Adipo Osteo Ref
PROTEASES
P00736 Complement component 1, r subcomponent serine protease 80 ex Y Y [69]
P09871 Complement component 1, s subcomponent serine protease 77 sp Y Y
P03956 Matrix metallopeptidase 1 (interstitial collagenase) collagen catabolism 54 sp Y
P08253 Matrix metallopeptidase 2, gelatinase A (MMP2) collagen catabolism 74 sp Y Y Y
Q15113 Procollagen C-endopeptidase enhancer collagen catabolism 48 sp Y
PROTEASE INHIBITORS
P05121 Serpin peptidase inhibitor, clade E, plasminogen activator inhibitor type 1(PAI-1) fibrinolysis 45 sp Y Y
P36955 Serpin peptidase inhibitor, clade F (PEDF) inhibitor of angiogenesis 46 sp Y
P05155 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 fibrinolysis 55 sp Y Y
P01033 TIMP metallopeptidase inhibitor 1 proteolysis inhibitor 23 sp Y Y Y
EXTRACELLULAR MATRIX COMPONENTS
P50454 Serpin H1 precursor (Collagen-binding protein) (Colligin) (47 kDa heat shock protein) 
(Proliferation-inducing gene 14 protein)
collagen-binding protein 46 sp Y
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein precursor ECM component 469 sp Y Y
P02452 Collagen, type I, alpha 1 ECM component 139 sp Y Y Y
P08123 Collagen, type I, alpha 2 ECM component 129 sp Y Y Y
P02461 Collagen, type III, alpha 1 ECM component 138 sp Y Y
P12109 Collagen, type VI, alpha 1 ECM component 108 sp Y Y Y
P12110 Collagen, type VI, alpha 2 ECM component 109 sp Y Y Y
P12111 Collagen, type VI, alpha 3 ECM component 343 sp Y Y Y
P07585 Decorin precursor (Bone proteoglycan II) ECM component 40 sp Y
P02751 Fibronectin precursor cell growth 26 sp Y Y Y
Q08380 Galectin-3-binding protein precursor (Lectin galactoside-binding soluble 3-binding protein) growth regulation/cell-matrix 65s p Y Y
Q16270 Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) cell adhesion 29 sp Y
P11047 Laminin gamma 1 chain precursor (Laminin B2 chain) ECM component 178 sp Y Y
P51884 Lumican precursor (Keratin sulfate proteoglycan lumican) ECM component 38 sp Y Y Y
P14543 Nidogen 1 ECM component 136 sp Y
Q15063 Periostin, osteoblast specific factor cell adhesion 93 sp Y Y
Q02809 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 pecursor collagen process 83 sp Y
O00391 Sulfhydryl oxidase 1 precursor, Quiescin Q6 (QSCN6) growth regulation 83 sp Y
P09486 Secreted protein, acidic, cysteine-rich (osteonectin) cell-matrix interaction 35 sp Y Y Y
Q15582 Transforming growth factor-beta-induced protein ig-h3 precursor (BIGH3) cell adhesion 75 sp Y Y Y
ANTI-INFLAMMATORY/ANTI-OXIDANT PROTEINS
Q12841 Follistatin-like 1 immunity and defense 35 sp Y Y Y
P09211 Glutathione S-transferase P antioxidant 23 ex Y [70, 71]
P26022 Pentraxin-related gene, rapidly induced by IL-1 beta (PTX3) inflammatory response 42 sp Y Y Y
P30041 PRDX6 peroxiredoxin 6 antioxidant 25 ex Y [72]
Q16881 TXNRD1 thioredoxin reductase 1 antioxidant 55 ex Y [33]
METABOLIC ENZYMES
Q04828* Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1) progesterone conversion 37 in Y
P06733 Enolase 1 (ENO1) glycolysis 47 ex Y Y Y [73, 74]
P04406 Glyceraldehyde-3-phosphate dehydrogenase glycolysis 36 ex Y Y Y [31]B
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P40926 Malate dehydrogenase 2, NAD (mitochondrial) Krebs cycle/gluconeogenesis 36 ex Y Y [75, 76]
P00558 Phosphoglycerate kinase 1 glycolysis 44 ex Y [32]
P18669 Phosphoglycerate mutase 1 glycolysis 29 ex Y [70]
P14618 Pyruvate kinase, muscle glycolysis 58 ex Y Y [77]
P29401 Transketolase pentose phosphate-glycolysis 68 ex Y Y [73]
P60174 Triosephosphate isomerase 1 glycolysis 27 ex Y [76]
CYTOSKELETAL COMPONENTS
P60709 Actin, beta cell growth 42 ex Y Y Y [70, 71]
P12814 Actinin, alpha 1 cell growth 103 ex Y Y [73, 74]
Q71U36 Alpha-3 tubulin cell growth 50 ex Y Y [73]
Q14019* Coactosin-like protein actin-binding protein 16 In Y
P15924 Desmoplakin cell adhesion 332 ex Y [77]
Q16555* Dihydropyrimidinase-like 2 tubulin binding protein 62 In Y
P14923* Junction plakoglobin cell adhesion 82 In Y
P09382 Lectin, galactoside-binding, soluble, 1 (galectin 1) growth regulation 15 ex Y [21]
P26038 Moesin cell-matrix interaction 68 ex Y Y Y [77]
P07737 Profilin 1 cell growth 15 ex Y Y [73]
Q15293* Reticulocalbin 1, EF-hand calcium binding domain calcium-binding protein 39 In Y
P08670 Vimentin cell growth 54 ex Y [71, 73]
P18206 Vinculin cell growth 124 ex Y Y [73]
O75083 WD repeat-containing protein 1 isoform 1 variant actin pol. control 66 ex Y Y [76]
HEAT SHOCK/PROTEIN FOLDING PROTEINS
P11021 78 kDa glucose-regulated protein precursor (GRP78) chaperone 72 sp Y Y Y
O43852 Calumenin precursor (Crocalbin) calcium-binding chaperone 37 sp Y Y Y
P27797 Calreticulin calcium-binding chaperone 48 sp Y Y
P50990* Chaperonin containing TCP1, subunit 8 (theta) chaperone 60 In Y
P68104 Elongation factor 1-alpha 1 (EF-1-alpha-1) protein biosynthesis 50 ex Y [78]
P11142 Heat shock 70 kDa protein 8 and homologs chaperone 71 ex Y [28]
Heat shock 70 kDa protein 2 (P54652), Heat shock 70 kDa protein 1-like (P43931)
P10809 Heat shock 60 kDa protein 1 (chaperonin) chaperone 61 ex Y [29]
P07900 Heat shock protein 90 kDa alpha (cytosolic), class A member 1 chaperone 85 ex Y [77]
P30101 PDIA3 protein disulfide-isomerase A3 precursor (EC 5.3.4.1) protein folding 57 sp Y Y Y
P23284 Peptidyl-prolyl cis-trans isomerase B precursor, (Rotamase) protein folding 23 sp Y Y Y
Q15084 Protein disulfide isomerase family A, member 6 protein folding 48 ex Y Y [71]
P14625 Endoplasmin precursor, (94 kDa glucose-regulated protein) (GRP94) (gp96 homolog) (Tumor 
rejection antigen 1)
chaperone 92 sp Y
OTHER PROTEINS
P41250 Glycyl-tRNA synthetase (EC 6.1.1.14) (Glycine – tRNA ligase) (GlyRS) tRNA synthetase 83 sp Y
Q9NTK5* Putative GTP-binding protein 9 (putative) GTP-binding protein 45 In Y
P50395 RAB GDP dissociation inhibitor beta vesicular transport 51 sp Y
P30153* Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform, (Medium 
tumor antigen-associated 61 kDa protein)
serine/threonine phosphatase 65 In Y
Y: indicates the presence of the candidate in the sample; sp: signal peptide; ex: extracellular; in: intracellular; Mw: molecular weight; adipo:day 3 adipocytes; osteo: day 3 osteoblasts; Loc: localisation; ref: 
reference. * indicates only putatively
Table 1: Identification of proteins in the secretome of hMADS cells at early step of adipogenesis and osteogenesis. (Continued)BMC Molecular Biology 2008, 9:26 http://www.biomedcentral.com/1471-2199/9/26
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day 3 for adipogenesis or osteogenesis). For all the candi-
dates, the results of immunoblotting/zymogram and a
semi-quantification of the bands are reported in Figure 4.
Matrix metallopeptidase 2 (MMP2), secreted protein,
acidic, cysteine-rich (SPARC) and ENO1 were secreted by
hMADS cells under all conditions, confirming the pattern
of detection obtained by SDS-PAGE-mass spectrometry
analysis (Fig. 4A–C, to be compared with Table 1). How-
ever, no significant difference was observed under the
three conditions for these candidates. Zymographic anal-
ysis of the secretion media revealed a prominent band of
Protein distribution of hMADS cell secretome Figure 2
Protein distribution of hMADS cell secretome. A. hMADS cell secretome is represented using a pie chart in three main 
groups: secreted proteins with signal peptide (sp, dashed area), secreted proteins without signal peptide (ex, white area) and 
intracellular proteins (in, dark area). The percentage of the proteins present in each group is reported in the scheme. One hun-
dred per cent is referred to a total number of 73 identified proteins. B. Venn diagram of proteins expressed under the differ-
ent culture conditions; n represents protein number in each condition.
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lysis at 66 kDa corresponding to the reported active form
of MMP2 (Fig. 4A). Addition of EDTA, an inhibitor of
gelatinase activity, led to the absence of lytic bands (data
not shown), thus confirming the specificity of MMP activ-
ity. Pigment epithelium derived factor (PEDF) was highly
expressed in day 3 adipocytes compared to day 0 and day
3 osteoblasts (Fig. 4D) in agreement with mass spectrom-
etry identification.
For 78 kDa glucose-regulated protein precursor (GRP78),
transforming growth factor-beta-induced protein
(BIGH3), pentraxin 3 (PTX3) and PAI-1, we confirmed
the pattern of detection reported in Table 1, with signifi-
cant differences of expression between day 0, day 3 adi-
pocytes and day 3 osteoblasts, as shown by Western blot
and histogram semi-quantifications (Fig. 4E–H).
Analysis of the plasminogen system in hMADS cells 
differentiating towards adipocytes and osteoblasts
Given the pattern of expression at the early step of adipo-
genesis and osteogenesis of hMADS cells, PAI-1 appeared
as one of the most promising candidates for investigating
further the adipocyte/osteoblast balance. PAI-1 mRNA
levels were similar to those of protein levels (Fig. 5A).
Since PAI-1 is a key regulator of the conversion of plas-
minogen to plasmin, negatively acting on two plasmino-
gen activators, namely uPA (urinary plasminogen
activator) and tPA (tissue type plasminogen activator)
[24], we decided to evaluate uPA and tPA levels in hMADS
Secretion levels of 8 candidates released from hMADS cells during the commitment to adipocytes and osteoblasts Figure 4
Secretion levels of 8 candidates released from hMADS cells during the commitment to adipocytes and osteob-
lasts. The activity of MMP2 has been evaluated by gelatin zymography (A). The expression of SPARC (B), ENO1(C), PEDF 
(D), GRP78 (E), BIGH3 (F), PTX3 (G) and PAI-1 (H) has been analyzed by Western blot. The bar graphs report the levels of 
expression of every single candidate as the mean of three independent experiments after 6 h of incubation. The values are indi-
cated as arbitrary units. *: p < 0.05. Two μg of secreted proteins have been loaded for each gel.
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cell secretome. ELISA experiments were performed on
secretion media from hMADS cells at day 0 and day 3
under adipogenic and osteogenic differentiating condi-
tions after 6 h of incubation. As reported in Figure 5B,
consistent with the immunoblotting data, PAI-1 levels
strongly decreased in differentiating adipocytes as com-
pared to day 0. By contrast, PAI-1 was secreted by day 3
osteoblasts, at albeit the same levels when compared to
day 0. Concerning tPA measurement, we did not detect
tPA in day 3 differentiating adipocytes, while a significant
increase of tPA levels was observed in day 3 osteoblasts as
compared to day 0 (Fig. 5C). By contrast, uPA remained
undetectable in the secretion media of hMADS cells under
the three conditions analyzed.
Enzymatic activities of uPA and tPA in 6 h serum-free con-
ditioned media of hMADS cells at d0 and day 3 of differ-
entiating adipocytes and osteoblasts were then evaluated
by casein/plasminogen zymographic analysis. As reported
in Figure 5D, tPA was mostly secreted by day 3 osteob-
Evaluation of the presence of the plasminogen system in hMADS cells Figure 5
Evaluation of the presence of the plasminogen system in hMADS cells. (A) PAI-1 mRNA levels have been deter-
mined in hMADS cells at day 0, day 3 adipocytes (adipo) and day 3 osteoblasts (osteo). (B) PAI-1 and (C) tPA protein levels 
have been measured by ELISA in the secretion media of hMADS cells at day 0, day 3 adipocytes (adipo) and day 3 osteoblasts 
(osteo) after 6 h of incubation. *: p < 0.05. (D) Zymographic analysis of plasminogen activators activity in hMADS cell condi-
tioned media collected after 6 h of incubation. A representative casein-plasminogen zymogram out of three independent 
experiments is shown. (E) RT-PCR analysis of UPAR expression in hMADS cells at day 0, day 3 adipocytes and day 3 osteob-
lasts. β-actin expression is reported as internal control. PCR products have been separated on a 1% agarose gel.
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lasts, as observed by the lytic band at 63 kDa, while uPA
was undetectable (expected band at 48 kDa), thus sup-
porting ELISA results. The higher band at around 110 kDa
may correspond to complexes between plasminogen acti-
vators and PAI-1 as classically reported [25]. Incubation of
the gel with amiloride, which selectively abrogates uPA-
dependent enzyme activities, did not affect tPA-depend-
ent lytic bands (data not shown). Furthermore, we dem-
onstrated that hMADS cells expressed uPA receptor
(UPAR) mRNA as reported by semi-quantitative RT-PCR
analysis (Fig. 5E). As these data actually suggest the
involvement of plasminogen activation in the regulation
of the fine balance between adipogenesis and osteogene-
sis, this hypothesis was next examined in a pathophysio-
logical situation where such an imbalance occurs.
PAI-I expression in ovariectomized mice
Disequilibrium of the adipocyte/osteoblast balance is
associated with the development of osteoporosis after
ovariectomy. It is well established that in the bone of ova-
riectomized (ovx) mice, adipocytes develop at expense of
bone formation [26,27]. In order to evaluate whether
osteoporosis affects PAI-1 in bone, we analyzed the
expression of PAI-1 mRNA in the humerus of ovx com-
pared to sham mice. Ten weeks after surgery, as previously
described [26] mice increased fat mass as shown by leptin
levels (Fig. 6A). As shown in Figure 6B, the levels of PAI-1
mRNA decreased significantly in the humerus of ovx com-
pared to sham mice, thus pointing out at PAI-1 modula-
tion in the adipocyte/osteoblast balance as a potential
marker of osteoporosis.
Discussion
Characterization of hMADS cell secretome
The secretome of murine and human adipocytes has been
characterized [19-22]. However, these studies primarily
focused on the late events of adipogenesis. Concerning
osteoblast secretome, a single detailed characterization
has been performed so far by Xiao and collaborators, who
analyzed the extracellular matrix vesicle proteome of min-
eralizing osteoblasts and identified proteins at late steps
of osteogenesis of MC3T3-E1 cells [28].
Herein, proteomic analysis has been used for the first time
to compare the secretome of hMADS cells differentiating
into adipocytes and osteoblasts and to gain insights into
the adipocyte/osteoblast balance. In order to delineate the
initial secretory events of adipogenesis and osteogenesis,
we performed a 6 h short term secretion which likely lim-
its the number of secreted proteins and cell lysis. A total of
73 proteins was identified and classified into 8 clusters.
The largest cluster corresponds to extracellular matrix pro-
teins, thus confirming the secretome characteristic of our
fraction. In addition, more than 50% of hMADS cell secre-
tome is represented by proteins with signal peptide.
Cytoskeletal proteins and heat shock and folding proteins
are also largely represented with 14 and 12 proteins,
respectively. Among the heat shock/folding proteins, two
chaperones, e.g. HSP60 and HSP70 were found. These
findings are reinforced by recent observations describing
the presence of HSP60 and HSP70 in the bloodstream.
HSP60 circulating levels in diabetic patients have been
found associated to cardiovascular diseases [29], while
elevated HSP70 circulating levels are related to systemic
inflammatory reaction in patients with heart failure fol-
lowing acute myocardial infarction [30]. In the metabolic
enzyme cluster, 9 enzymes were also found, including
glyceraldehyde dehydrogenase (GAPDH) and phos-
phoglycerate kinase (PGK). According to literature, extra-
cellular GAPDH, also found in rat serum, inhibits
spreading of COS-7 cells [31], while PGK is secreted by
tumor cells and its activity is regulated by hypoxia [32].
These enzymes might reflect increased metabolic require-
ments, but they could also exert independent and still
undiscovered functions. Anti-oxidant proteins, like
Thioredoxin reductase 1 (TXNRD1), represent another
cluster of proteins secreted by hMADS cells. TXNRD1, that
does not exhibit a signal peptide, has been described in rat
as a circulating protein [33].
Eleven percent of secreted proteins from hMADS cells is
however represented by intracellular proteins, presence of
which has not been reported up to now outside the cells.
A modest contamination by uncontrolled release of intra-
PAI-1 mRNA levels in the humerus of ovariectomized as  compared to control mice Figure 6
PAI-1 mRNA levels in the humerus of ovariect-
omized as compared to control mice. A. Plasma leptin 
levels have been determined by ELISA. B. PAI-1 mRNA 
expression has been evaluated by qRT-PCR in the humerus 
of ovx and sham mice and standardized with TBP expression 
levels. The data are expressed as the mean ± SD per group of 
4 mice. *: p < 0.05.
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cellular proteins cannot be excluded despite the fact that
no cell lysis was detected. Although cell death can take
place in culture and is unavoidably accompanied by a
subsequent release of cytosolic components, it should be
pointed out that cell viability was not affected [see Addi-
tional file 1]. Among non-artifactual explanations, it is
worth pointing out that this phenomenon could impli-
cate exosome secretion, as most of the identified proteins
were reported to be present in exosomes. Exosomes are
membrane vesicles that originate from the cell membrane
and are released extracellularly [34]. Their occurrence has
been also described in the bloodstream and in different
tissues in vivo [35], suggesting their participation in phys-
iological and/or pathological processes. To date, the exact
function of exosomes in vivo is not completely under-
stood. A large number of cell types, including reticulo-
cytes, immune cells, platelets, epithelial cells, dendritic
cells and others (see [34] and [36] for detailed reviews)
appears to secrete exosomes either as a mechanism to
extrude some proteins and/or to communicate between
cells and/or to play immune functions. Typically, exo-
somes contain chaperones, cytoskeletal proteins (moesin,
desmoplakin), elongation factors and several enzymes
(ENO1), as described in literature through proteomic
analysis of the secretion media from different sources as
well as from analysis by flow cytometry and Western blot
[34,37]. Therefore intracellular proteins recovered outside
hMADS cells may be a mere reflection of events taking
place within the cytosol at the time of exosome formation.
Furthermore, 4 (Q14019, Q15293, P50990 and P30153)
out of 8 candidates, known to be intracellular, have a
score higher than a fixed threshold when analyzed using
software predicting a non-classical protein secretion [38],
it is likely that these proteins are secreted by non-tradi-
tional mechanisms and did not arise from cell lysis.
Clearly, these proteins can only be considered as puta-
tively secreted and their actual secretion should be
assessed.
Selected candidates of hMADS cell secretome
Mass spectrometry data have been validated for 8 selected
candidates. MMP2, SPARC and ENO1 displayed no signif-
icant differences in terms of quantification by immunob-
lotting or zymogram when comparing the three culture
conditions.
MMP2, a zinc-dependent endopeptidase, involved in the
degradation of the ECM, is actively secreted by adipocytes
[39] and osteoblasts [40]. The presence of MMP2 in
hMADS cells reinforces the concept that ECM remodelling
represents a crucial event during the early steps of differ-
entiation. As observed in this study, SPARC has been
already described as a secreted molecule in both adi-
pocytes [41] and osteoblasts [42]. SPARC is reported to be
up-regulated in the adipose tissue of different models of
murine obesity [41] and its circulating levels correlate
with body mass index in humans [43]. A potential interest
in further studying SPARC in the adipocyte/osteoblast
balance relies upon the fact that bone marrow stromal
cells from SPARC-null mice tend to form more adipocytes
than cells from wild type mice [44]. ENO1 is mainly
described for its role as an intracellular glycolytic enzyme,
however its presence extracellularly has been already
reported in the secretion medium of 3T3-L1 adipocytes
[21], as well as in other cellular models [45]. ENO1 is a
multifunctional protein and a putative plasminogen
receptor, since it has been reported as a cell surface protein
[46]. Therefore, a potential role of ENO1 in the plasmino-
gen cascade cannot be excluded.
Concerning the five other candidates (PEDF, GRP78,
BIGH3, PTX3 and PAI-1), relevant differences of expres-
sion between day 0 and day 3 of adipogenesis and osteo-
genesis have been found. PEDF has been reported to be
preferentially secreted by 3T3-L1 preadipocytes as com-
pared to fully differentiated adipocytes [20]. However,
Zvonic et al. [22] have described an increase in PEDF
expression during adipogenesis of primary cultures of
human adipose-derived stem cells, in agreement with our
observations in hMADS cells when comparing hMADS
cells at day 0 and after complete adipocyte differentiation
(data not shown). PEDF could represent a valuable candi-
date for the adipocyte/osteoblast balance given its expres-
sion also in differentiating hMADS osteoblasts. A putative
role for PEDF as mediator of angiogenesis and in matrix
remodelling of the bone has been recently postulated
[47].
Several molecular chaperones have been found in the
secretome of hMADS cells, including calumenin, calreti-
culin, protein disulfide isomerase 6, heat shock proteins
and GRP78. As GRP78 controls intracellular protein trans-
port [48], its up-regulation in hMADS differentiating adi-
pocytes and osteoblasts as compared to day 0 could reflect
an increased demand in protein folding or a protection
against endoplasmic reticulum stress.
BIGH3 is reported to be down-regulated during the differ-
entiation of murine osteoblasts and to play negative
effects on the early stages of osteogenesis [49]. In hMADS
cells, BIGH3 protein levels increase in differentiating oste-
oblasts as compared to day 0, however a decrease during
osteoblast terminal differentiation was observed (data not
shown). Interestingly, BIGH3 is also released by differen-
tiating adipocytes at day 3. So far, no report has described
the secretion of BIGH3 by adipocytes or adipose tissue,
whereas BIGH3 is involved in distinct cellular functions,
such as cell growth, tumorigenesis, wound healing, apop-
tosis and migration [50]. Thus a role for BIGH3 in adipo-
genesis remains to be established.BMC Molecular Biology 2008, 9:26 http://www.biomedcentral.com/1471-2199/9/26
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PTX3 is a member of the pentraxin family that we
described to be secreted by adipocytes and to respond to
inflammatory stimuli such as TNFα [51]. In differentiat-
ing hMADS cells, PTX3 appears up-regulated during both
adipogenesis and osteogenesis. The presence of PTX3 in
osteoblasts has never been reported; we speculate that,
under conditions of stress or inflammation, PTX3 could
represent a potential target of the adipocyte/osteoblast
balance that might deserve further studies.
Finally, PAI-1 represents another member of the serpin
family which is secreted by hMADS cells. PAI-1 is a pleio-
tropic molecule, exerting functional roles in wound heal-
ing, atherosclerosis, tumor angiogenesis, rheumatoid
arthritis, fibrosis etc., besides its main role as regulator of
fibrinolysis [52]. In addition, PAI-1 plays a role in meta-
bolic disorders such as obesity and insulin resistance, rep-
resenting a marker of metabolic syndrome [53]. A role for
PAI-1 in bone remodeling has been postulated, since mice
lacking PAI-1 are protected from trabecular bone loss after
ovariectomy, suggesting a site-specific role for PAI-1 in
bone turnover [54]. Altogether, these data indicate that
PAI-1 should represent a reliable candidate for the study
of the adipocyte/osteoblast balance. In hMADS cell secre-
tome, PAI-1 signal disappears at day 3 of adipogenesis
while remaining present in differentiating osteoblasts.
Despite some demonstration that PAI-1 is produced by
adipocytes during adipogenesis [53], it was recently
shown that adipogenesis, as such, may not induce PAI-1;
rather it enhances the potential of adipocytes to respond
to PAI-1 inducers [55]. This may explain why PAI-1 syn-
thesis dropped after differentiation of human adipocytes
cultured in the absence of serum, known to contain sev-
eral PAI-1 inducers [56,57]. Moreover overexpression of
PAI-1 by adenovirus-mediated gene transfer inhibited adi-
pocyte differentiation [58]. Conversely, preadipocytes
from PAI-1-/- mice showed greater differentiation than
those issued from wild type mice [58]. This suggests that
not only PAI-1 is dispensable for adipocyte differentiation
but could even be deleterious as it has been recently sug-
gested that bone marrow-derived PAI-1 had an effect on
the development of obesity through its effect in inflam-
mation [59].
tPA is also preferentially secreted by hMADS differentiat-
ing osteoblasts, while no detectable levels of uPA have
been detected, despite the presence of UPAR mRNA. Inter-
estingly, PAI-1 and tPA serum levels have been reported as
putative non-invasive diagnostic biomarkers of idiopathic
osteonecrosis of the femoral head [60]. As for circulating
PAI-1, a correlation with dysbaric osteonecrosis has been
also described [61]. These data strongly suggest that the
plasminogen/plasmin system could represent a potential
target for further investigation of the adipocyte/osteoblast
balance. Even if preliminary, our data concerning a
decrease of PAI-1 mRNA levels in bone of ovx as com-
pared to sham mice clearly indicate that PAI-1 expression
is modulated under conditions altering the adipocyte/
osteoblast balance, such as osteoporosis.
Conclusion
In conclusion, we have characterized the secretome of
hMADS cells during the early events of adipogenesis and
osteogenesis using a proteomic approach. hMADS cell
secretome is represented by bona fide secreted proteins,
proteins secreted through non-classical pathways and
intracellular proteins, the presence of which in the extra-
cellular medium being likely due to exosome secretion.
Eight clusters have been identified, including proteases,
protease inhibitors, ECM components, anti-inflamma-
tory-antioxidant proteins, metabolic enzymes, cytoskele-
tal components, heat-shock/protein folding proteins and
other proteins. Among the 8 selected proteins, PAI-1 con-
stitutes the most promising candidate for further studies
owing to the role of the plasminogen/plasmin system in
adipogenesis and bone remodeling.
Methods
Materials
Cell culture media were purchased from Cambrex and
FCS from Dutscher S.A. (Brumath, France). EGF was a
product of Euromedex (Souffelweyersheim, France). Anti-
bodies directed against ENO1, PEDF, BIGH3 and SPARC
were supplied from Santa Cruz Biotechnology (Santa
Cruz, CA), Chemicon International (Temecula, CA), R&D
Systems (Minneapolis, MN) and Haematologic Technolo-
gies Inc. (Essex Junction, VT), respectively. PAI-1 antibody
was a kind gift from Prof. PJ Declerck, (Leuven, Belgium).
Rat anti-human PTX-3 antibody was kindly provided by
Prof. A Mantovani [62]. Reverse transcriptase and trypsin
were from Promega (Charbonnières-les-Bains, France).
PVDF membranes were from Amersham Biosciences
(Orsay, France). Complete protease inhibitor cocktail was
from Roche Diagnostics (Meylan, France). All the other
products were from Sigma-Aldrich (Saint Quentin Falla-
vier, France).
Cell culture
The establishment and characterization of the multipo-
tency and self-renewal of hMADS cells have already been
described [14-16]. In the experiments reported herein,
hMADS-2 cells, established from the pubic region fat pad
of a 5-year old male donor, were used at passages between
16 and 35 corresponding to 35 to 100 population dou-
blings. Cells were seeded at a density of 5000 cells/cm2 in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% FCS, 2.5 ng/ml hFGF2, 60 μg/ml peni-
cillin and 50 μg/ml streptomycin. The medium was
changed every other day and hFGF2 was removed when
cells reached confluence. At day 2 post-confluence (desig-BMC Molecular Biology 2008, 9:26 http://www.biomedcentral.com/1471-2199/9/26
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nated as day 0) adipogenic or osteogenic differentiation
was induced, as described previously [14,17]. Briefly, for
adipogenic differentiation hMADS cells were induced to
differentiate in the presence of DMEM/Ham's F12 media
supplemented with 0.85 μM insulin, 0.2 nM triiodothyro-
nine, 10 μg/ml transferrin, 1 μM dexamethasone (DEX)
and 500 μM isobutyl-methylxanthine (IBMX). Three days
later, the medium was changed (DEX and IBMX omitted)
and 100 nM Rosiglitazone was added up to day 9. For
osteogenic differentiation, cells were induced to differen-
tiate in α-MEM containing 1% FCS supplemented with 10
nM 1,25-dihydroxyvitamin D3, 100 nM DEX, 10 μM L-
ascorbic acid phosphate, 10 mM β-glycerophosphate and
10 ng/ml EGF. For both differentiation protocols, the
media were then changed every other day and cells were
used at the indicated days.
Lactate dehydrogenase (LDH) activity has been per-
formed as described previously [63]. Briefly, the activity
has been measured in the culture media and compared to
that obtained from cells treated with a detergent in order
to release the whole intracellular LDH activity.
Animals
Eight weeks old C57Bl/6J mice were subjected either to
bilateral ovariectomies (ovx) from the dorsal approach or
to sham surgery during which the ovaries were exterior-
ized but replaced intact by the operator (Charles River,
L'Arbresle, France). Mice were housed in local animal
facility for a period of 10 weeks following surgery to await
the development of osteoporosis. Animals were sacrificed
with carbon dioxide according to the guidelines of the
local animal care and experimentation committee. RNA
from humerus was extracted using Totally RNA™ kit
according to manufacturer's instructions (Ambion, Court-
aboeuf, France).
Sample preparation
Conditioned media for each condition (24 ml, corre-
sponding to 8 dishes of 100 mm diameter) were collected
on ice, centrifuged and filtered to remove cell debris, if
any, and supplemented with complete protease inhibitor
cocktail. Twelve ml of the samples were concentrated by
ultra-filtration (Millipore, Centricon, 5 kDa cut-off). Pro-
tein concentrations were determined using Bio-Rad Pro-
tein Assay reagent (Bio-Rad, Marnes-la-Coquette, France)
and were: 0.12 ± 0.04, 0.15 ± 0.06; 0.12 ± 0.02 μg/μl for
day 0, day 3 adipocyte and day 3 osteoblast respectively.
One-dimensional polyacrylamide gel electrophoresis
One-dimensional polyacrylamide gel electrophoresis
(SDS-PAGE) was performed using Bio-Rad mini-Protean
system. Gels were stained with Bio-Safe Coomassie Stain
(Bio-Rad) for 2 h at room temperature and rinsed with
water, according to manufacturer's instructions.
Trypsin digestion and Mass Spectrometry
After Coomassie staining, the whole lanes were manually
excised into 10 bands which were processed for tryptic
digestion according to a standard protocol. Briefly, after a
washing step with 50% ethanol, proteins were reduced
and alkylated with 10 mM DTT and 50 mM iodoaceta-
mide, respectively. The spots were washed twice with 50%
ethanol, shrunken with acetonitrile (ACN) and then sub-
sequently digested with 100 ng of trypsin in 50 mM
ammonium bicarbonate, 15% ACN. The peptides were
extracted with 0.5% TFA, 50% ACN then 100% ACN. LC-
MS/MS mass spectrometry was performed with a Surveyor
system coupled with an LCQ DECA XP ion trap mass spec-
trometer (ThermoQuest, San Jose, CA). Peptides were sep-
arated on a C18 column (300 μm × 10 cm, Hypersil,
ThermoQuest) at 5 μl/min with 1 to 40 % ACN gradient
in 0.1 % formic acid. A 3 kV voltage was applied on the
micro-ESI needle and the automatic acquisition was set as
previously described [64].
Fragmentation spectra acquired by Xcalibur 1.3 (Thermo-
Electron Corp.) were searched with Sequest (Bio-Works
version 3.3, Thermo Electron Corp.) against the Swiss-
Prot protein database (235 673 entries,
uniprot_sprot.fasta file downloaded on October 2006
from [65]). Sequest parameters were: i) peptide mass tol-
erance of 1.7 Da, ii) parent ion masses treated as monoi-
sotopic,  iii) fragmentation ion masses treated as
monoisotopic with 1.0 Da mass tolerance, iv) trypsin (KR,
strictly enzymatic specificity at the both ends) and two
miss cleavages, v) a 57.0 Da static modification on
cysteines accounted for alkylation and a 16.0-Da variable
modification on methionine accounted for oxidation.
Sequest results were filtered with the following require-
ments:  i) at least 2 peptides were required for protein
identification, ii) peptides identified as first candidate, iii)
Xcorr > 1.7, 2.2 and 3.3 for mono-, di- and tri-charged
peptides, iv) P value up to 0.001 for peptide. The filters'
relevance was checked with different tryptic digests as con-
trol (HSP90, albumin, lactoglobulin) and using the differ-
ent SDS-PAGE molecular weight markers; filters
automatically removed all the proteins from Bioworks
results sheet with the exception of the exact identification.
To address the database redundancy issue, only identifica-
tions with highest scoring and corresponding to human
protein references were selected. Protein classification has
been performed using annotation from Bioinformatic
Harvester [66] and Swiss-Prot Protein database [67].
RNA extraction, RT-PCR and quantitative RT-PCR 
analysis (qRT-PCR)
Total RNA was isolated with TRI-Reagent kit (Euromedex,
France) according to the manufacturer's instructions.
Reverse transcriptase reactions and semi-quantitative PCRBMC Molecular Biology 2008, 9:26 http://www.biomedcentral.com/1471-2199/9/26
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assays were performed as already described [14,51]. PCR
products (25 cycles) were analyzed by 1.5% agarose gel
electrophoresis visualized by ethidium-bromide staining.
qRT-PCR assays were run on an ABI Prism 7000 real-time
PCR machine (PerkinElmer Life Sciences). Reactions were
performed according to manufacturer's instructions using
SYBR green master mix (Eurogentec, France). The expres-
sion of selected genes was normalized to the expression of
the TATA-binding protein (TBP) encoding gene. Gene
expression was quantified using the comparative-delta Ct
method.
Primer sequences and annealing temperatures are
reported in Table 2S [see Additional file 3].
Immunoblotting
Equal amounts of proteins (2 μg) were denatured,
reduced and separated on 12% polyacrylamide-SDS gels.
Proteins were transferred in 25 mM Tris, 192 mM glycine
and 20% ethanol onto PVDF membrane. Blots were
blocked for 30 min with TBS (10 mM Tris-HCl pH 7.5 and
150 mM NaCl) plus 0.1% Tween 20 (TTBS buffer) con-
taining 5% dried milk powder (blocking buffer) and then
hybridized in the same buffer with specific primary anti-
bodies (0.2 μg/ml) at 4°C. After overnight incubation, the
blots were washed twice in TTBS and incubated 1 hr at
room temperature in blocking buffer using the appropri-
ate secondary antibodies (Sigma). After 5 washes in TTBS,
immunoreactive proteins were visualized using the ECL
chemiluminescence's detection kit (Amersham) accord-
ing to the manufacturer's instructions.
Determination of MMP activity by gelatin zymography
Proteins with gelatinolytic activity were identified by elec-
trophoresis in 10% SDS-PAGE containing 1 mg/ml gela-
tin. Two μg of secretion media were directly loaded on
gels under nonreducing conditions. After electrophoresis,
proteins were renatured by washing twice with 2.5% Tri-
ton X-100 in 50 mM Tris-HCl pH 7.4. The gels were then
incubated at 37°C for 16 h in an activation buffer (50 mM
Tris-HCl pH 7.4, 5 mM CaCl2 and 0.2 M NaCl) and
stained with Coomassie Brilliant Blue R-250 (in 40%
methanol and 10% acetic acid). Destaining was per-
formed in the same buffer in the absence of the dye.
Migration of proteins was compared with that of a
prestained molecular weight marker. EDTA (15 mM) was
added to the incubation buffer in parallel gels, in order to
inhibit cation-dependent enzymatic activities.
Determination of uPA and tPA activities by casein-
plasminogen zymography
Two  μg of conditioned media were analyzed on 10%
polyacrylamide gels containing 1 mg/ml alpha-casein and
10 μg/ml plasminogen (Sigma), under nonreducing con-
ditions. After the electrophoretic run, gels were rinsed
once in 100 mM glycine buffer with 2.5% Triton-X 100 for
45 min and then incubated overnight at 37°C in 100 mM
glycine buffer, 15 mM EDTA, pH 8.0. Identical gels were
incubated in the above buffers containing 500 μM amilo-
ride, in order to discriminate uPA from tPA bands. Gels
were then stained with a 0.25% Coomassie Blue/10% ace-
tic acid/40% methanol solution for 1 hr, followed by
destaining in a 40% methanol/10% acetic acid mixture.
Caseinolytic activity resulting from plasminogen activa-
tion was visualized by white lytic bands on a blue back-
ground after conversion of plasminogen to plasmin by
uPA and tPA. Molecular weights were calculated from the
position of prestained markers that were subjected to elec-
trophoresis in parallel lanes. No lytic bands were observed
in plasminogen-free gels.
ELISA
Supernatant PAI-1 antigen was assayed using ELISA's spe-
cific for human PAI-1, as previously described [68]. PAI-1
ELISA detects latent and active forms of human PAI-1 and
PAI-1 complexes. The assay is insensitive to PAI-2. The
amount of uPA and tPA antigen was measured with the
Immunobind uPA ELISA kit (American Diagnostic,
Greenwich, CT) and the commercially available kit Asser-
achrom tPA (Diagnostica Stago, France) according to the
instructions of the manufacturer. Inactive and active
forms of plasminogen activators are all recognized by the
ELISA kit. Plasma concentration of leptin was measured
by ELISA using EIA kit (SPI-Bio, France).
Statistical analysis
Data are expressed as mean values ± standard deviation
(SD). qRT-PCR and ELISA data and quantifications of
immunoblot/zymogram experiments were analyzed
using Student's t-test. Statistical significance was assumed
at p level <0.05.
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